FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147874539> ?p ?o ?g. }

• W2147874539 endingPage "274" @default.
• W2147874539 startingPage "266" @default.
• W2147874539 abstract "2-Methoxyestradiol (2-ME), an endogenous metabolite of estradiol with no affinity for estrogen receptors, is a potent anticarcinogenic agent (in phase II clinical trials) and mediates the inhibitory effects of estradiol on smooth muscle cell (SMC) growth. Here we studied the intracellular mechanisms by which 2-ME inhibits SMC growth and whether 2-ME prevents injury-induced neointima formation. 2-ME concentrations that inhibit proliferation of cycling human aortic SMCs by >or=50% blocked cell-cycle progression in G(0)/G(1) and in G(2)/M phase, as determined by flow cytometry. Consistent with the cell-cycle effects, at a molecular level (Western blots), 2-ME inhibited cyclin D(1) and cyclin B(1) expression; cyclin-dependent kinase (cdk)-1 and cdk-2 activity; and retinoblastoma protein (pRb), extracellular signal-regulated kinase (ERK) 1/2, and Akt phosphorylation. 2-ME also upregulated the Cdk inhibitor p27 and interfered with tubulin polymerization. Moreover, 2-ME augmented COX-2 expression, suggesting that it may also inhibit SMC growth via prostaglandin formation. In rats, treatment with 2-ME abrogated injury-induced neointima formation; decreased proliferating SMCs; downregulated expression of proliferating-cell nuclear antigen (PCNA), c-myc, cyclin D(1), cyclin B(1), phosphorylated Akt, phosphorylated ERK1/2, p21, and pRb; inhibited cdk-1 and cdk-4 activity; and upregulated expression of cyclooxygenase (COX)-2 and p27. Caspase-3 cleavage assay and fluorescence-activated cell-sorting (FACS) analysis showed no evidence of apoptosis in 2-ME-treated SMCs, and TUNEL staining in carotid segments showed no evidence of 2-ME-induced apoptosis in vivo. The antimitotic effects of 2-ME on SMCs are mediated by the inhibition of key cell-cycle regulatory proteins and effects on tubulin polymerization and COX-2 upregulation. These effects of 2-ME most likely contribute to the antivasoocclusive actions of this endogenous compound." @default.
• W2147874539 created "2016-06-24" @default.
• W2147874539 creator A5005780035 @default.
• W2147874539 creator A5011938389 @default.
• W2147874539 creator A5013481804 @default.
• W2147874539 creator A5042375385 @default.
• W2147874539 creator A5043621293 @default.
• W2147874539 creator A5089739552 @default.
• W2147874539 date "2006-08-04" @default.
• W2147874539 modified "2023-10-11" @default.
• W2147874539 title "2-Methoxyestradiol, an Estradiol Metabolite, Inhibits Neointima Formation and Smooth Muscle Cell Growth via Double Blockade of the Cell Cycle" @default.
• W2147874539 cites W1965987801 @default.
• W2147874539 cites W1970708444 @default.
• W2147874539 cites W1998948981 @default.
• W2147874539 cites W2018732635 @default.
• W2147874539 cites W2021797949 @default.
• W2147874539 cites W2024417910 @default.
• W2147874539 cites W2032615620 @default.
• W2147874539 cites W2058088398 @default.
• W2147874539 cites W2087375731 @default.
• W2147874539 cites W2092409818 @default.
• W2147874539 cites W2138052582 @default.
• W2147874539 cites W2158054014 @default.
• W2147874539 cites W2158887393 @default.
• W2147874539 cites W2168229293 @default.
• W2147874539 cites W2186358774 @default.
• W2147874539 cites W2321438790 @default.
• W2147874539 cites W76930537 @default.
• W2147874539 doi "https://doi.org/10.1161/01.res.0000233318.85181.2e" @default.
• W2147874539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16794187" @default.
• W2147874539 hasPublicationYear "2006" @default.
• W2147874539 type Work @default.
• W2147874539 sameAs 2147874539 @default.
• W2147874539 citedByCount "88" @default.
• W2147874539 countsByYear W21478745392012 @default.
• W2147874539 countsByYear W21478745392013 @default.
• W2147874539 countsByYear W21478745392014 @default.
• W2147874539 countsByYear W21478745392015 @default.
• W2147874539 countsByYear W21478745392016 @default.
• W2147874539 countsByYear W21478745392017 @default.
• W2147874539 countsByYear W21478745392018 @default.
• W2147874539 countsByYear W21478745392019 @default.
• W2147874539 countsByYear W21478745392020 @default.
• W2147874539 countsByYear W21478745392021 @default.
• W2147874539 countsByYear W21478745392022 @default.
• W2147874539 countsByYear W21478745392023 @default.
• W2147874539 crossrefType "journal-article" @default.
• W2147874539 hasAuthorship W2147874539A5005780035 @default.
• W2147874539 hasAuthorship W2147874539A5011938389 @default.
• W2147874539 hasAuthorship W2147874539A5013481804 @default.
• W2147874539 hasAuthorship W2147874539A5042375385 @default.
• W2147874539 hasAuthorship W2147874539A5043621293 @default.
• W2147874539 hasAuthorship W2147874539A5089739552 @default.
• W2147874539 hasBestOaLocation W21478745391 @default.
• W2147874539 hasConcept C124320809 @default.
• W2147874539 hasConcept C126322002 @default.
• W2147874539 hasConcept C153911025 @default.
• W2147874539 hasConcept C16438837 @default.
• W2147874539 hasConcept C185592680 @default.
• W2147874539 hasConcept C190283241 @default.
• W2147874539 hasConcept C2777339539 @default.
• W2147874539 hasConcept C2778283817 @default.
• W2147874539 hasConcept C2778583881 @default.
• W2147874539 hasConcept C29537977 @default.
• W2147874539 hasConcept C55493867 @default.
• W2147874539 hasConcept C62112901 @default.
• W2147874539 hasConcept C62478195 @default.
• W2147874539 hasConcept C71924100 @default.
• W2147874539 hasConcept C75217442 @default.
• W2147874539 hasConcept C86803240 @default.
• W2147874539 hasConcept C95444343 @default.
• W2147874539 hasConceptScore W2147874539C124320809 @default.
• W2147874539 hasConceptScore W2147874539C126322002 @default.
• W2147874539 hasConceptScore W2147874539C153911025 @default.
• W2147874539 hasConceptScore W2147874539C16438837 @default.
• W2147874539 hasConceptScore W2147874539C185592680 @default.
• W2147874539 hasConceptScore W2147874539C190283241 @default.
• W2147874539 hasConceptScore W2147874539C2777339539 @default.
• W2147874539 hasConceptScore W2147874539C2778283817 @default.
• W2147874539 hasConceptScore W2147874539C2778583881 @default.
• W2147874539 hasConceptScore W2147874539C29537977 @default.
• W2147874539 hasConceptScore W2147874539C55493867 @default.
• W2147874539 hasConceptScore W2147874539C62112901 @default.
• W2147874539 hasConceptScore W2147874539C62478195 @default.
• W2147874539 hasConceptScore W2147874539C71924100 @default.
• W2147874539 hasConceptScore W2147874539C75217442 @default.
• W2147874539 hasConceptScore W2147874539C86803240 @default.
• W2147874539 hasConceptScore W2147874539C95444343 @default.
• W2147874539 hasIssue "3" @default.
• W2147874539 hasLocation W21478745391 @default.
• W2147874539 hasLocation W21478745392 @default.
• W2147874539 hasOpenAccess W2147874539 @default.
• W2147874539 hasPrimaryLocation W21478745391 @default.
• W2147874539 hasRelatedWork W1972305847 @default.
• W2147874539 hasRelatedWork W2130069836 @default.
• W2147874539 hasRelatedWork W2132066963 @default.
• W2147874539 hasRelatedWork W2135393026 @default.
• W2147874539 hasRelatedWork W2141091145 @default.

• next